Clinical Trials
9 trialsNCT05662202 2026-05-22
Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
Biofrontera Inc.
Phase 3 Active not recruiting
NCT05060237 2024-10-17
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
Biofrontera Bioscience GmbH
Phase 1 Completed
NCT02144077 2022-11-03
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT04319159 2021-11-11
Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)
Biofrontera Bioscience GmbH
Phase 1 Completed
NCT02464709 2019-08-28
Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)
Joint Authority for Päijät-Häme Social and Health Care
Phase 4 Completed
NCT02367547 2019-03-28
Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL
Joint Authority for Päijät-Häme Social and Health Care
Phase 1/2 Unknown
NCT02685592 2018-05-30
LM PDT
Joint Authority for Päijät-Häme Social and Health Care
Phase 4 Completed
NCT02799069 2017-04-28
Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT02799082 2017-04-06
Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.
Biofrontera Bioscience GmbH
Phase 3 Completed